Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 2

Phase II Randomized Trial of Neo-Adjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation Versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)

NCT ID: NCT03493425Sponsor: ECOG-ACRIN Cancer Research GroupLast updated: 2026-06-18

Summary

This randomized phase II trial studies how well chemotherapy before surgery and radiation therapy works compared to surgery and radiation therapy alone in treating patients with nasal and paranasal sinus cancer that can be removed by surgery. Drugs used in chemotherapy, such as docetaxel, cisplatin, and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy before surgery and radiation therapy may make the tumor smaller and reduce the amount of normal tissue that needs to be removed and treated with radiation.

Detailed description

PRIMARY OBJECTIVES: I. Evaluate the structure preservation rate for patients with locally advanced resectable nasal and paranasal sinus squamous cell carcinoma (NPNSCC) with or without neoadjuvant therapy; all patients will undergo surgical resection and postoperative standard care. II. Evaluate overall survival (OS) for patients with locally advanced resectable NPNSCC with or without neoadjuvant therapy followed by surgical resection and postoperative standard care. SECONDARY OBJECTIVES: I. Evaluate progression-free survival (PFS) for this patient population. II. Examine the rate of structure preservation for the orbit (freedom from orbital exenteration). III. Evaluate site reported p16 data and correlate with outcome. IV. Determine the accuracy of baseline/post-chemotherapy magnetic resonance imaging (MRI) and fludeoxyglucose F-18 positron emission tomography/computed tomography (FDG PET/CT)-based prediction of orbit and skull base preservation. V. Determine the accuracy of baseline/post-chemotherapy MRI and/or FDG PET/CT-based prediction of 2-year overall survival. TERTIARY OBJECTIVES: I. To determine the effects of tobacco, operationalized as combustible tobacco (1a), other forms of tobacco (1b), and environmental tobacco exposure (ETS) (1c) on provider-reported cancer-treatment toxicity (adverse events \[both clinical and hematologic\] and dose modifications). II. To determine the effects of tobacco on patient-reported physical symptoms and psychological symptoms. III. To examine quitting behaviors and behavioral counseling/support and cessation medication utilization. IV. To explore the effect of tobacco use and exposure on treatment duration, relative dose intensity, and therapeutic benefit. OUTLINE: Patients are randomized to 1 of 2 arms. ARM A: Patients undergo standard of care surgery. Beginning 4-6 weeks after surgery, patients undergo image guided intensity modulated radiation therapy (IMRT) once daily (QD) for 5 fractions per week for 30 fractions. Patients with positive margins/positive extracapsular spread (ECS) in lymph nodes undergo image guided IMRT QD for 5 fractions per week for 30 fractions and cisplatin intravenously (IV) over 1-2 hours or carboplatin IV over 30 minutes (for patients who are ineligible to receive cisplatin) weekly for 6 weeks in the absence of disease progression or unacceptable toxicity. ARM B: Patients receive docetaxel IV over 1 hour and cisplatin IV over 1-2 hours on day 1. Patients who are ineligible to receive cisplatin receive carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery no later than 6 weeks following the last dose of chemotherapy. Beginning 4-6 weeks after surgery, patients undergo image guided IMRT QD for 5 fractions per week for 30 fractions. Patients with positive margins/positive ECS in lymph nodes undergo image guided IMRT QD for 5 fractions per week for 30 fractions and cisplatin IV over 1-2 hours or carboplatin IV over 30 minutes (for patients who are ineligible to receive cisplatin) weekly for 6 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months if \< 2 years from study entry and then every 6 months if 2-5 years from study entry.

Arms & interventions

  • DrugCarboplatin

    Given IV

  • DrugCisplatin

    Given IV

  • DrugDocetaxel

    Given IV

  • RadiationImage Guided Radiation Therapy

    Undergo image guided IMRT

  • RadiationIntensity-Modulated Radiation Therapy

    Undergo image guided IMRT

  • OtherLaboratory Biomarker Analysis

    Correlative studies

  • OtherQuestionnaire Administration

    Ancillary studies

  • ProcedureTherapeutic Conventional Surgery

    Undergo standard of care surgery

Outcome measures

Primary

  • Structure preservation rate defined as both skull base and orbit being preserved

    Fisher?s exact test will be used to compare the structure preservation rate between the two arms. The comparison between the two arms for structure preservation will be conducted separately (each at one-sided 0.05 significance level).

    Time frame: Up to 5 years

  • Overall survival (OS)

    Log rank test will be used to compare OS between the two arms. The comparison between the two arms for OS will be conducted separately (each at one-sided 0.05 significance level).

    Time frame: From date of randomization, censoring follow-up at last date of contact, assessed for up to 5 years

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * General physical condition compatible with the proposed chemotherapy and surgery * Stage T3 or T4a, histologically-confirmed NPNSCC requiring orbital or skull base resection: * Stages T3 and T4a disease will be included regardless of nodal status (N0 or N1-3), provided that surgical therapy would require orbital or skull base resection * The surgical oncologist in each institution will determine the need for resection of the orbit OR base of skull at baseline for patients on both Arms A and B and following neo-adjuvant chemotherapy for patients on Arm B * Resection of skull base will be deemed necessary according to skull base bone erosion by CT or marrow involvement by MRI is noted; for any disease abutting the skull base; or for ethmoid sinus or frontal sinus involvement * Resection of orbital contents will be deemed necessary according to skull base society guidelines, based on involvement of periorbital fat documented by MRI imaging * Patients must be deemed surgically resectable by the surgical teams at each institution and must have a determination of degree of anticipated structure preservation of orbit and skull base; this needs to be determined prior to randomization * Patients may not be receiving investigational agents at time of registration, or at any time while on study and during the 4 weeks preceding enrollment * Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to docetaxel and/or both platinum-based chemotherapy agents are excluded; patient must be able to receive at least one of the two proposed chemotherapy regimens * Patients with evidence of distant metastases or leptomeningeal disease (LMD) are excluded * Patients must not have received previous irradiation for head and neck tumor, skull base, or brain tumors * Patients with uncontrolled inter-current illnesses which in the opinion of the investigator will interfere with the ability to undergo therapy including chemotherapy are excluded * Patients with a history of a different malignancy are excluded, unless the disease has not progressed for \>= 2 years * Absolute neutrophil count (ANC) \> 1500/mm\^3 =\< 2 weeks prior to randomization * Hemoglobin (Hgb) \> 8.0 g/dL =\< 2 weeks prior to randomization * Platelet count \> 100,000/mm\^3 =\< 2 weeks prior to randomization * Creatinine clearance of \> 60 ml/min; creatinine clearance may be measured or calculated; if calculating, creatinine clearance, use the Cockroft-Gault formula =\< 2 weeks prior to randomization * Total bilirubin within normal limits (must be obtained =\< 2 weeks prior to randomization) * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) must be within the range allowing for eligibility, must be obtained \< 2 weeks prior to randomization * Alkaline phosphatase must be within the range allowing for eligibility, must be obtained \< 2 weeks prior to randomization * Patients with a prior history of squamous cell or basal carcinoma of the skin or in situ cervical cancer must have been curatively treated * No current peripheral neuropathy \> grade 2 at time of randomization * Patients must not have any co-existing condition that would preclude full compliance with the study; no prior history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80 * Women must not be pregnant or breast-feeding * All females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy * A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) * Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the study * Patients must have measurable disease; MRI and/or PET/CT scans need to be performed within 2 weeks prior to registration

Study locations (140)

University of Arizona Cancer Center-Orange Grove Campus

Tucson, Arizona, 85704

Recruiting
Site Public Contact · Contact
520-694-8900
Christopher Le · Principal Investigator

Banner University Medical Center - Tucson

Tucson, Arizona, 85719

Recruiting
Site Public Contact · Contact
aselegue@email.arizona.edu
Christopher Le · Principal Investigator

University of Arizona Cancer Center-North Campus

Tucson, Arizona, 85719

Recruiting
Site Public Contact · Contact
800-327-2873
Christopher Le · Principal Investigator

Mercy Hospital Fort Smith

Fort Smith, Arkansas, 72903

Recruiting
Site Public Contact · Contact
800-378-9373
Jay W. Carlson · Principal Investigator

UC San Diego Moores Cancer Center

La Jolla, California, 92093

Withdrawn

Stanford Cancer Institute Palo Alto

Palo Alto, California, 94304

Recruiting
Site Public Contact · Contact
650-498-7061ccto-office@stanford.edu
Peter H. Hwang · Principal Investigator

VA Palo Alto Health Care System

Palo Alto, California, 94304

Recruiting
Site Public Contact · Contact
800-455-0057
Harlan A. Pinto · Principal Investigator

Smilow Cancer Center/Yale-New Haven Hospital

New Haven, Connecticut, 06510

Recruiting
Site Public Contact · Contact
203-785-5702canceranswers@yale.edu
Barbara A. Burtness · Principal Investigator

Yale University

New Haven, Connecticut, 06520

Recruiting
Site Public Contact · Contact
203-785-5702canceranswers@yale.edu
Barbara A. Burtness · Principal Investigator

UM Sylvester Comprehensive Cancer Center at Coral Gables

Coral Gables, Florida, 33146

Suspended

UM Sylvester Comprehensive Cancer Center at Deerfield Beach

Deerfield Beach, Florida, 33442

Recruiting
Site Public Contact · Contact
305-243-2647
Ruben Carmona · Principal Investigator

University of Miami Miller School of Medicine-Sylvester Cancer Center

Miami, Florida, 33136

Recruiting
Site Public Contact · Contact
305-243-2647
Ruben Carmona · Principal Investigator

UM Sylvester Comprehensive Cancer Center at Plantation

Plantation, Florida, 33324

Recruiting
Site Public Contact · Contact
305-243-2647
Ruben Carmona · Principal Investigator

Moffitt Cancer Center-International Plaza

Tampa, Florida, 33607

Recruiting
Site Public Contact · Contact
800-679-0775ClinicalTrials@moffitt.org
Christine H. Chung · Principal Investigator

Moffitt Cancer Center - McKinley Campus

Tampa, Florida, 33612

Recruiting
Site Public Contact · Contact
800-679-0775ClinicalTrials@moffitt.org
Christine H. Chung · Principal Investigator

Moffitt Cancer Center

Tampa, Florida, 33612

Recruiting
Site Public Contact · Contact
800-679-0775ClinicalTrials@moffitt.org
Christine H. Chung · Principal Investigator

Emory Proton Therapy Center

Atlanta, Georgia, 30308

Recruiting
Site Public Contact · Contact
404-251-2854allyson.anderson@emory.edu
Dong M. Shin · Principal Investigator

Emory University Hospital Midtown

Atlanta, Georgia, 30308

Recruiting
Site Public Contact · Contact
888-946-7447
Dong M. Shin · Principal Investigator

Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, 30322

Recruiting
Site Public Contact · Contact
404-778-1868
Dong M. Shin · Principal Investigator

Saint Alphonsus Cancer Care Center-Boise

Boise, Idaho, 83706

Recruiting
Site Public Contact · Contact
734-712-3671stephanie.couch@stjoeshealth.org
John M. Schallenkamp · Principal Investigator

Saint Alphonsus Cancer Care Center-Caldwell

Caldwell, Idaho, 83605

Recruiting
Site Public Contact · Contact
734-712-3671stephanie.couch@stjoeshealth.org
John M. Schallenkamp · Principal Investigator

Kootenai Health - Coeur d'Alene

Coeur d'Alene, Idaho, 83814

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Idaho Urologic Institute-Meridian

Meridian, Idaho, 83642

Recruiting
Site Public Contact · Contact
734-712-3671stephanie.couch@stjoeshealth.org
John M. Schallenkamp · Principal Investigator

Saint Alphonsus Medical Center-Nampa

Nampa, Idaho, 83686

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Kootenai Clinic Cancer Services - Post Falls

Post Falls, Idaho, 83854

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Rush - Copley Medical Center

Aurora, Illinois, 60504

Recruiting
Site Public Contact · Contact
630-978-6212Cancer.Research@rushcopley.com
Vamsi K. Vasireddy · Principal Investigator

Northwestern University

Chicago, Illinois, 60611

Active Not Recruiting

Rush University Medical Center

Chicago, Illinois, 60612

Recruiting
Site Public Contact · Contact
312-942-5498clinical_trials@rush.edu
Michael J. Jelinek · Principal Investigator

Carle on Vermilion

Danville, Illinois, 61832

Recruiting
Site Public Contact · Contact
800-446-5532Research@carle.com
Vamsi K. Vasireddy · Principal Investigator

Carle Physician Group-Effingham

Effingham, Illinois, 62401

Recruiting
Site Public Contact · Contact
800-446-5532Research@carle.com
Vamsi K. Vasireddy · Principal Investigator

NorthShore University HealthSystem-Evanston Hospital

Evanston, Illinois, 60201

Recruiting
Site Public Contact · Contact
847-570-2109
Nicholas P. Campbell · Principal Investigator

NorthShore University HealthSystem-Glenbrook Hospital

Glenview, Illinois, 60026

Recruiting
Site Public Contact · Contact
847-570-2109
Nicholas P. Campbell · Principal Investigator

NorthShore University HealthSystem-Highland Park Hospital

Highland Park, Illinois, 60035

Recruiting
Site Public Contact · Contact
847-570-2109
Nicholas P. Campbell · Principal Investigator

Carle Physician Group-Mattoon/Charleston

Mattoon, Illinois, 61938

Recruiting
Site Public Contact · Contact
800-446-5532Research@carle.com
Vamsi K. Vasireddy · Principal Investigator

Good Samaritan Regional Health Center

Mount Vernon, Illinois, 62864

Recruiting
Site Public Contact · Contact
618-242-4600
Jay W. Carlson · Principal Investigator

Carle Cancer Center

Urbana, Illinois, 61801

Recruiting
Site Public Contact · Contact
800-446-5532Research@carle.com
Vamsi K. Vasireddy · Principal Investigator

The Carle Foundation Hospital

Urbana, Illinois, 61801

Recruiting
Site Public Contact · Contact
800-446-5532Research@carle.com
Vamsi K. Vasireddy · Principal Investigator

Saint Anthony Regional Hospital

Carroll, Iowa, 51401

Recruiting
Site Public Contact · Contact
515-689-7658sbenson@iora.org
Joshua Lukenbill · Principal Investigator

Iowa Methodist Medical Center

Des Moines, Iowa, 50309

Recruiting
Site Public Contact · Contact
515-241-6727
Joshua Lukenbill · Principal Investigator

Medical Oncology and Hematology Associates-Des Moines

Des Moines, Iowa, 50309

Recruiting
Site Public Contact · Contact
515-282-2921
Joshua Lukenbill · Principal Investigator

Broadlawns Medical Center

Des Moines, Iowa, 50314

Recruiting
Site Public Contact · Contact
515-282-2200
Joshua Lukenbill · Principal Investigator

Iowa Lutheran Hospital

Des Moines, Iowa, 50316

Recruiting
Site Public Contact · Contact
515-241-8704
Joshua Lukenbill · Principal Investigator

Methodist West Hospital

West Des Moines, Iowa, 50266-7700

Recruiting
Site Public Contact · Contact
515-343-1000
Joshua Lukenbill · Principal Investigator

Central Care Cancer Center - Garden City

Garden City, Kansas, 67846

Recruiting
Site Public Contact · Contact
913-948-5588aroland@kccop.org
Jay W. Carlson · Principal Investigator

Central Care Cancer Center - Great Bend

Great Bend, Kansas, 67530

Recruiting
Site Public Contact · Contact
913-948-5588aroland@kccop.org
Jay W. Carlson · Principal Investigator

University of Kansas Cancer Center

Kansas City, Kansas, 66160

Active Not Recruiting

Lawrence Memorial Hospital

Lawrence, Kansas, 66044

Active Not Recruiting

Olathe Health Cancer Center

Olathe, Kansas, 66061

Active Not Recruiting

University of Kansas Cancer Center-Overland Park

Overland Park, Kansas, 66210

Active Not Recruiting

Ascension Via Christi - Pittsburg

Pittsburg, Kansas, 66762

Active Not Recruiting

Salina Regional Health Center

Salina, Kansas, 67401

Active Not Recruiting

University of Kansas Health System Saint Francis Campus

Topeka, Kansas, 66606

Active Not Recruiting

University of Kansas Hospital-Westwood Cancer Center

Westwood, Kansas, 66205

Active Not Recruiting

The James Graham Brown Cancer Center at University of Louisville

Louisville, Kentucky, 40202

Recruiting
Site Public Contact · Contact
502-562-3429
Neal E. Dunlap · Principal Investigator

Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114

Suspended

University of Michigan Comprehensive Cancer Center

Ann Arbor, Michigan, 48109

Recruiting
Site Public Contact · Contact
800-865-1125
Paul L. Swiecicki · Principal Investigator

Henry Ford Cancer Institute-Downriver

Brownstown, Michigan, 48183

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Ding Wang · Principal Investigator

Henry Ford Macomb Hospital-Clinton Township

Clinton Township, Michigan, 48038

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Ding Wang · Principal Investigator

Henry Ford Medical Center-Fairlane

Dearborn, Michigan, 48126

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Ding Wang · Principal Investigator

Wayne State University/Karmanos Cancer Institute

Detroit, Michigan, 48201

Recruiting
Site Public Contact · Contact
313-576-9790ctoadmin@karmanos.org
Ammar Sukari · Principal Investigator

Henry Ford Hospital

Detroit, Michigan, 48202

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Ding Wang · Principal Investigator

Weisberg Cancer Treatment Center

Farmington Hills, Michigan, 48334

Recruiting
Site Public Contact · Contact
313-576-9790ctoadmin@karmanos.org
Ammar Sukari · Principal Investigator

Allegiance Health

Jackson, Michigan, 49201

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Ding Wang · Principal Investigator

Henry Ford Medical Center-Columbus

Novi, Michigan, 48377

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Ding Wang · Principal Investigator

Henry Ford Macomb Health Center - Shelby Township

Shelby, Michigan, 48315

Recruiting
Site Public Contact · Contact
313-916-1784tpearce1@hfhs.org
Ding Wang · Principal Investigator

Henry Ford West Bloomfield Hospital

West Bloomfield, Michigan, 48322

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Ding Wang · Principal Investigator

Sanford Joe Lueken Cancer Center

Bemidji, Minnesota, 56601

Recruiting
Site Public Contact · Contact
218-333-5000OncologyClinicalTrialsFargo@sanfordhealth.org
Preston D. Steen · Principal Investigator

Saint Louis Cancer and Breast Institute-Ballwin

Ballwin, Missouri, 63011

Recruiting
Site Public Contact · Contact
314-251-7058
Jay W. Carlson · Principal Investigator

Central Care Cancer Center - Bolivar

Bolivar, Missouri, 65613

Recruiting
Site Public Contact · Contact
913-948-5588aroland@kccop.org
Jay W. Carlson · Principal Investigator

Siteman Cancer Center at Saint Peters Hospital

City of Saint Peters, Missouri, 63376

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Douglas R. Adkins · Principal Investigator

Siteman Cancer Center at West County Hospital

Creve Coeur, Missouri, 63141

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Douglas R. Adkins · Principal Investigator

Freeman Health System

Joplin, Missouri, 64804

Recruiting
Site Public Contact · Contact
417-347-4030LJCrockett@freemanhealth.com
Jay W. Carlson · Principal Investigator

Mercy Hospital Joplin

Joplin, Missouri, 64804

Recruiting
Site Public Contact · Contact
417-556-3074esmeralda.carrillo@mercy.net
Jay W. Carlson · Principal Investigator

University of Kansas Cancer Center - North

Kansas City, Missouri, 64154

Active Not Recruiting

University of Kansas Cancer Center at North Kansas City Hospital

North Kansas City, Missouri, 64116

Active Not Recruiting

Delbert Day Cancer Institute at PCRMC

Rolla, Missouri, 65401

Recruiting
Site Public Contact · Contact
573-458-7504research@phelpshealth.org
Jay W. Carlson · Principal Investigator

Mercy Clinic-Rolla-Cancer and Hematology

Rolla, Missouri, 65401

Recruiting
Site Public Contact · Contact
573-458-6379
Jay W. Carlson · Principal Investigator

Heartland Regional Medical Center

Saint Joseph, Missouri, 64506

Recruiting
Site Public Contact · Contact
816-271-7937linda.schumacher@mymlc.com
Jay W. Carlson · Principal Investigator

Mercy Hospital Springfield

Springfield, Missouri, 65804

Recruiting
Site Public Contact · Contact
417-269-4520
Jay W. Carlson · Principal Investigator

CoxHealth South Hospital

Springfield, Missouri, 65807

Recruiting
Site Public Contact · Contact
417-269-4520
Jay W. Carlson · Principal Investigator

Washington University School of Medicine

St Louis, Missouri, 63110

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Douglas R. Adkins · Principal Investigator

Mercy Hospital South

St Louis, Missouri, 63128

Recruiting
Site Public Contact · Contact
janet.lesko@mercy.net
Jay W. Carlson · Principal Investigator

Siteman Cancer Center-South County

St Louis, Missouri, 63129

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Douglas R. Adkins · Principal Investigator

Siteman Cancer Center at Christian Hospital

St Louis, Missouri, 63136

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Douglas R. Adkins · Principal Investigator

Mercy Hospital Saint Louis

St Louis, Missouri, 63141

Recruiting
Site Public Contact · Contact
314-251-7066
Jay W. Carlson · Principal Investigator

Billings Clinic Cancer Center

Billings, Montana, 59101

Recruiting
Site Public Contact · Contact
800-996-2663research@billingsclinic.org
John M. Schallenkamp · Principal Investigator

Bozeman Deaconess Hospital

Bozeman, Montana, 59715

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Benefis Healthcare- Sletten Cancer Institute

Great Falls, Montana, 59405

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Great Falls Clinic

Great Falls, Montana, 59405

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Kalispell Regional Medical Center

Kalispell, Montana, 59901

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Community Medical Hospital

Missoula, Montana, 59804

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, 07920

Recruiting
Site Public Contact · Contact
212-639-7592
Marc Cohen · Principal Investigator

Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748

Recruiting
Site Public Contact · Contact
212-639-7592
Marc Cohen · Principal Investigator

Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645

Recruiting
Site Public Contact · Contact
212-639-7592
Marc Cohen · Principal Investigator

Northwell Health Imbert Cancer Center

Bay Shore, New York, 11706

Recruiting
Site Public Contact · Contact
516-734-8896
Maged Ghaly · Principal Investigator

Roswell Park Cancer Institute

Buffalo, New York, 14263

Recruiting
Site Public Contact · Contact
800-767-9355askroswell@roswellpark.org
Anurag K. Singh · Principal Investigator

Northwell Health/Center for Advanced Medicine

Lake Success, New York, 11042

Recruiting
Site Public Contact · Contact
516-734-8896
Maged Ghaly · Principal Investigator

Long Island Jewish Medical Center

New Hyde Park, New York, 11040

Recruiting
Site Public Contact · Contact
516-734-8896
Maged Ghaly · Principal Investigator

Lenox Hill Hospital

New York, New York, 10021

Recruiting
Site Public Contact · Contact
516-734-8896
Maged Ghaly · Principal Investigator

Mount Sinai Hospital

New York, New York, 10029

Recruiting
Site Public Contact · Contact
212-824-7309CCTO@mssm.edu
Marshall R. Posner · Principal Investigator

Memorial Sloan Kettering Cancer Center

New York, New York, 10065

Recruiting
Site Public Contact · Contact
212-639-7592
Marc Cohen · Principal Investigator

University of Rochester

Rochester, New York, 14642

Recruiting
Site Public Contact · Contact
585-275-5830
Paul M. Barr · Principal Investigator

Montefiore Medical Center-Einstein Campus

The Bronx, New York, 10461

Recruiting
Site Public Contact · Contact
718-379-6866eskwak@montefiore.org
Balazs Halmos · Principal Investigator

Montefiore Medical Center-Weiler Hospital

The Bronx, New York, 10461

Recruiting
Site Public Contact · Contact
718-379-6866eskwak@montefiore.org
Balazs Halmos · Principal Investigator

Montefiore Medical Center - Moses Campus

The Bronx, New York, 10467

Recruiting
Site Public Contact · Contact
718-379-6866eskwak@montefiore.org
Balazs Halmos · Principal Investigator

UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, 27599

Recruiting
Site Public Contact · Contact
877-668-0683cancerclinicaltrials@med.unc.edu
Colette Shen · Principal Investigator

Sanford Bismarck Medical Center

Bismarck, North Dakota, 58501

Recruiting
Site Public Contact · Contact
701-323-5760OncologyClinicalTrialsFargo@sanfordhealth.org
Preston D. Steen · Principal Investigator

Sanford Broadway Medical Center

Fargo, North Dakota, 58122

Recruiting
Site Public Contact · Contact
701-323-5760OncologyClinicalTrialsFargo@sanfordhealth.org
Preston D. Steen · Principal Investigator

Sanford Roger Maris Cancer Center

Fargo, North Dakota, 58122

Recruiting
Site Public Contact · Contact
701-234-6161OncologyClinicalTrialsFargo@sanfordhealth.org
Preston D. Steen · Principal Investigator

University of Cincinnati Cancer Center-UC Medical Center

Cincinnati, Ohio, 45219

Recruiting
Site Public Contact · Contact
513-584-7698cancer@uchealth.com
Vinita Takiar · Principal Investigator

University of Cincinnati Cancer Center-West Chester

West Chester, Ohio, 45069

Recruiting
Site Public Contact · Contact
513-584-7698cancer@uchealth.com
Vinita Takiar · Principal Investigator

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104

Active Not Recruiting

Mercy Hospital Oklahoma City

Oklahoma City, Oklahoma, 73120

Recruiting
Site Public Contact · Contact
405-752-3402
Jay W. Carlson · Principal Investigator

UPMC-Heritage Valley Health System Beaver

Beaver, Pennsylvania, 15009

Recruiting
Site Public Contact · Contact
412-389-5208haneydl@upmc.edu
Dan P. Zandberg · Principal Investigator

UPMC Cancer Centers - Arnold Palmer Pavilion

Greensburg, Pennsylvania, 15601

Recruiting
Site Public Contact · Contact
724-838-1900
Dan P. Zandberg · Principal Investigator

UPMC Pinnacle Cancer Center/Community Osteopathic Campus

Harrisburg, Pennsylvania, 17109

Recruiting
Site Public Contact · Contact
717-724-6765klitchfield@PINNACLEHEALTH.org
Dan P. Zandberg · Principal Investigator

UPMC Jameson

New Castle, Pennsylvania, 16105

Suspended

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107

Recruiting
Site Public Contact · Contact
215-600-9151ONCTrialNow@jefferson.edu
Rita S. Axelrod · Principal Investigator

UPMC-Presbyterian Hospital

Pittsburgh, Pennsylvania, 15213

Recruiting
Site Public Contact · Contact
412-647-2811
Dan P. Zandberg · Principal Investigator

University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, 15232

Recruiting
Site Public Contact · Contact
412-647-8073
Dan P. Zandberg · Principal Investigator

UPMC-Shadyside Hospital

Pittsburgh, Pennsylvania, 15232

Recruiting
Site Public Contact · Contact
412-621-2334
Dan P. Zandberg · Principal Investigator

UPMC-Passavant Hospital

Pittsburgh, Pennsylvania, 15237

Recruiting
Site Public Contact · Contact
412-367-6454
Dan P. Zandberg · Principal Investigator

UPMC Washington Hospital Radiation Oncology

Washington, Pennsylvania, 15301

Recruiting
Site Public Contact · Contact
724-223-3788cancer@washingtonhospital.org
Dan P. Zandberg · Principal Investigator

Sanford Cancer Center Oncology Clinic

Sioux Falls, South Dakota, 57104

Recruiting
Site Public Contact · Contact
605-312-3320OncologyClinicTrialsSF@sanfordhealth.org
Preston D. Steen · Principal Investigator

Sanford USD Medical Center - Sioux Falls

Sioux Falls, South Dakota, 57117-5134

Recruiting
Site Public Contact · Contact
605-312-3320OncologyClinicalTrialsSF@SanfordHealth.org
Preston D. Steen · Principal Investigator

Parkland Memorial Hospital

Dallas, Texas, 75235

Active Not Recruiting

UT Southwestern/Simmons Cancer Center-Dallas

Dallas, Texas, 75390

Active Not Recruiting

UT Southwestern Clinical Center at Richardson/Plano

Richardson, Texas, 75080

Active Not Recruiting

Inova Schar Cancer Institute

Fairfax, Virginia, 22031

Recruiting
Site Public Contact · Contact
703-720-5210Stephanie.VanBebber@inova.org
John F. Deeken · Principal Investigator

Inova Fairfax Hospital

Falls Church, Virginia, 22042

Recruiting
Site Public Contact · Contact
703-208-6650Stephanie.VanBebber@inova.org
John F. Deeken · Principal Investigator

Marshfield Medical Center-EC Cancer Center

Eau Claire, Wisconsin, 54701

Recruiting
Site Public Contact · Contact
800-782-8581oncology.clinical.trials@marshfieldresearch.org
Nagy Elsayyad · Principal Investigator

Marshfield Medical Center-Marshfield

Marshfield, Wisconsin, 54449

Recruiting
Site Public Contact · Contact
800-782-8581oncology.clinical.trials@marshfieldresearch.org
Nagy Elsayyad · Principal Investigator

Medical College of Wisconsin

Milwaukee, Wisconsin, 53226

Active Not Recruiting

Marshfield Clinic-Minocqua Center

Minocqua, Wisconsin, 54548

Recruiting
Site Public Contact · Contact
800-782-8581oncology.clinical.trials@marshfieldresearch.org
Nagy Elsayyad · Principal Investigator

Marshfield Medical Center-Rice Lake

Rice Lake, Wisconsin, 54868

Recruiting
Site Public Contact · Contact
800-782-8581oncology.clinical.trials@marshfieldresearch.org
Nagy Elsayyad · Principal Investigator

Marshfield Clinic Stevens Point Center

Stevens Point, Wisconsin, 54482

Recruiting
Site Public Contact · Contact
800-782-8581oncology.clinical.trials@marshfieldresearch.org
Nagy Elsayyad · Principal Investigator

Marshfield Clinic-Wausau Center

Wausau, Wisconsin, 54401

Suspended

Diagnostic and Treatment Center

Weston, Wisconsin, 54476

Recruiting
Site Public Contact · Contact
888-799-3989oncology.clinical.trials@marshfieldresearch.org
Robert A. Nordal · Principal Investigator

Marshfield Medical Center - Weston

Weston, Wisconsin, 54476

Recruiting
Site Public Contact · Contact
800-782-8581oncology.clinical.trials@marshfieldresearch.org
Nagy Elsayyad · Principal Investigator

Welch Cancer Center

Sheridan, Wyoming, 82801

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

References

  • Adilbay D, Valero C, Fitzgerald C, Yuan A, Mimica X, Gupta P, Wong RJ, Shah JP, Patel SG, Ganly I, Cohen MA. Outcomes in surgical management of sinonasal malignancy-A single comprehensive cancer center experience. Head Neck. 2022 Apr;44(4):933-942. doi: 10.1002/hed.26989. Epub 2022 Jan 25.(PubMed)